Статья
Поражения сердца у больных COVID-19
Новая коронавирусная инфекция COVID-19 – высококонтагиозное вирусное заболевание с развитием острого тяжелого респираторного синдрома, в основе которого лежит развитие выраженного тромбовоспалительного синдрома. По мере увеличения количества больных COVID-19 появились публикации относительно поражения сердца, особенно у пациентов с тяжелыми и критическими формами заболевания. В настоящем обзоре описываются роль рецептора ангиотензинпревращающего фермента 2‑го типа в регуляции внедрения вируса, разнообразие поражения сердца, коронарных артерий, а также значение артериальной гипертензии и применение блокаторов ренин-ангиотензин-альдостероновой системы в прогнозе больных COVID-19.
1. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiology. 2020;5(7):802–10. DOI: 10.1001/jamacardio.2020.0950
2. Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nature Reviews Microbiology. 2019;17(3):181–92. DOI: 10.1038/s41579-018-0118-9
3. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. DOI: 10.1038/s41586-020-2012-7
4. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN et al. Aerosol and Surface Stability of SARSCoV-2 as Compared with SARS-CoV-1. New England Journal of Medicine. 2020;382(16):1564–7. DOI: 10.1056/NEJMc2004973
5. Zhao S, Lin Q, Ran J, Musa SS, Yang G, Wang W et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak. International Journal of Infectious Diseases. 2020;92:214–7. DOI: 10.1016/j.ijid.2020.01.050
6. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Medical Research. 2020;7(1):11. DOI: 10.1186/s40779-020-00240-0
7. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020;63(3):364–74. DOI: 10.1007/s11427-020-1643-8
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3
9. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-292.e6. DOI: 10.1016/j.cell.2020.02.058
10. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–8. DOI: 10.1126/science.abb2762
11. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M et al. The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7). Physiological Reviews. 2018;98(1):505–53. DOI: 10.1152/physrev.00023.2016
12. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4. DOI: 10.1038/nature02145
13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052
14. Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury. Virologica Sinica. 2020;35(3):256–8. DOI: 10.1007/s12250-020-00205-6
15. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology. 2004;203(2):631–7. DOI: 10.1002/path.1570
16. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. The Lancet Infectious Diseases. 2020;20(5):533–4. DOI: 10.1016/S1473-3099(20)30120-1
17. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A et al. COVID-19 and Cardiovascular Disease. Circulation. 2020;141(20):1648–55. DOI: 10.1161/CIRCULATIONAHA.120.046941
18. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Critical Care. 2020;24(1):108. DOI: 10.1186/s13054-020-2833-7
19. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28(7):1195–9. DOI: 10.1002/oby.22831
20. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology. 2020;146(1):110–8. DOI: 10.1016/j.jaci.2020.04.006
21. Cai Q, Chen F, Wang T, Luo F, Liu X, Wu Q et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392–8. DOI: 10.2337/dc20-0576
22. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine. 2020;180(7):934–43. DOI: 10.1001/jamainternmed.2020.0994
23. Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T et al. Hypertension and related diseases in the era of COVID-19: areport from the Japanese Society of Hypertension Task Force on COVID-19. Hypertension Research. 2020;43(10):1028–46. DOI: 10.1038/s41440-020-0515-0
24. Centers for Disease Control and Prevention. People at Increased Risk for Severe Illness. 2020.Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html
25. Williams B, Zhang Y. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. The Lancet. 2020;395(10238):1671–3. DOI: 10.1016/S0140-6736(20)31131-4
26. Kuster GM, Pfister O, Burkard T, Zhou Q, Twerenbold R, Haaf P et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? European Heart Journal. 2020;41(19):1801–3. DOI: 10.1093/eurheartj/ehaa235
27. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac AngiotensinConverting Enzyme 2. Circulation. 2005;111(20):2605–10. DOI: 10.1161/CIRCULATIONAHA.104.510461
28. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent Mechanism. Hypertension. 2014;64(6):1368–75. DOI: 10.1161/HYPERTENSIONAHA.114.03743
29. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653–9. DOI: 10.1056/NEJMsr2005760
30. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020;75(6):1382–5. DOI: 10.1161/HYPERTENSIONAHA.120.15082
31. Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases. 2020;43(3):219–22. DOI: 10.3760/cma.j.issn.1001-0939.2020.03.016
32. de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a casepopulation study. The Lancet. 2020;395(10238):1705–14. DOI: 10.1016/S0140-6736(20)31030-8
33. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiology. 2020;5(7):825–30. DOI: 10.1001/jamacardio.2020.1624
34. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. New England Journal of Medicine. 2020;382(25):2431–40. DOI: 10.1056/NEJMoa2006923
35. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A et al. Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust. European Journal of Heart Failure. 2020;22(6):967–74. DOI: 10.1002/ejhf.1924
36. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circulation Research. 2020;126(12):1671–81. DOI: 10.1161/CIRCRESAHA.120.317134
37. American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Av. at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. 2020.
38. European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. 2020.Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang
39. Шляхто Е.В., Конради А.О., Арутюнов Г.П., Арутюнов А.Г., Баутин А.Е., Бойцов С.А. и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020;25(3):129-48. DOI: 10.15829/1560-4071-2020-3-3801
40. Lopes RD, Macedo AVS, de Barros e Silva PGM, Moll-Bernardes RJ, Feldman A, D’Andréa Saba Arruda G et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The BRACE CORONA Trial. American Heart Journal. 2020;226:49–59. DOI: 10.1016/j.ahj.2020.05.002
41. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 10 June 2020. Av. at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.
42. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(7):811–8. DOI: 10.1001/jamacardio.2020.1017
43. Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020;17(5):259–60. DOI: 10.1038/s41569-020-0360-5
44. Cosyns B, Lochy S, Luchian ML, Gimelli A, Pontone G, Allard SD et al. The role of cardiovascular imaging for myocardial injury in hospitalized COVID-19 patients. European Heart Journal Cardiovascular Imaging. 2020;21(7):709–14. DOI: 10.1093/ehjci/jeaa136
45. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(7):819–24. DOI: 10.1001/jamacardio.2020.1096
46. Yancy CW, Fonarow GC. Coronavirus Disease 2019 (COVID-19) and the Heart—Is Heart Failure the Next Chapter? JAMA Cardiology. 2020;5(11):1216–7. DOI: 10.1001/jamacardio.2020.3575
47. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. European Heart Journal. 2020;41(22):2070–9. DOI: 10.1093/eurheartj/ehaa408
48. Toth E, Dancy L, Amin-Youssef G, Papachristidis A, Dworakowski R. Collateral implications of the COVID-19 pandemic: belated presentation of infective endocarditis in a young patient. European Heart Journal. 2020;41(45):4365. DOI: 10.1093/eurheartj/ehaa633
49. Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. European Heart Journal. 2020;41(22):2130. DOI: 10.1093/eurheartj/ehaa253
50. Kesici S, Aykan HH, Orhan D, Bayrakci B. Fulminant COVID-19-related myocarditis in an infant. European Heart Journal. 2020;41(31):3021. DOI: 10.1093/eurheartj/ehaa515
51. Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. European Heart Journal. 2020;41(19):1861–2. DOI: 10.1093/eurheartj/ehaa286
52. Solano-López J, Sánchez-Recalde A, Zamorano JL. SARS-CoV-2, a novel virus with an unusual cardiac feature: inverted takotsubo syndrome. European Heart Journal. 2020;41(32):3106. DOI: 10.1093/eurheartj/ehaa390
53. Meyer P, Degrauwe S, Van Delden C, Ghadri J-R, Templin C. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. European Heart Journal. 2020;41(19):1860. DOI: 10.1093/eurheartj/ehaa306
54. Bonnet M, Champagnac A, Lantelme P, Harbaoui B. Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2. European Heart Journal. 2020;41(39):3863–4. DOI: 10.1093/eurheartj/ehaa588
55. Shergill S, Davies J, Bloomfield J. Florid aortitis following SARSCoV-2 infection. European Heart Journal. 2020;41(44):4286. DOI: 10.1093/eurheartj/ehaa635
56. Wichmann D, Sperhake J-P, Lütgehetmann M, Steurer S, Edler C, Heinemann A et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Annals of Internal Medicine. 2020;173(4):268–77. DOI: 10.7326/M20-2003
57. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C et al. Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series. Annals of Internal Medicine. 2020;173(5):350–61. DOI: 10.7326/M20-2566
58. Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Critical Care and Resuscitation. 2020;22(2):95–7. PMID: 32294809
59. Сугралиев А.Б, Cirillo P. Тромбо-воспалительный обструктивный синдром при COVID-19. Место и роль антикоагулянтной терапии в лечении COVID-19. Медицина (Алматы). 2020;3-4:2-7
60. Hu D, Liu K, Li B, Hu Z. Large intracardiac thrombus in a COVID-19 patient treated with prolonged extracorporeal membrane oxygenation implantation. European Heart Journal. 2020;41(32):3104–5. DOI: 10.1093/eurheartj/ehaa524
61. Ueki Y, Otsuka T, Windecker S, Räber L. ST-elevation myocardial infarction and pulmonary embolism in a patient with COVID-19 acute respiratory distress syndrome. European Heart Journal. 2020;41(22):2134. DOI: 10.1093/eurheartj/ehaa399
62. Dominguez-Erquicia P, Dobarro D, Raposeiras-Roubín S, BastosFernandez G, Iñiguez-Romo A. Multivessel coronary thrombosis in a patient with COVID-19 pneumonia. European Heart Journal. 2020;41(22):2132. DOI: 10.1093/eurheartj/ehaa393
63. Fernandez Gasso L, Maneiro Melon NM, Sarnago Cebada F, Solis J, Garcia Tejada J. Multivessel spontaneous coronary artery dissection presenting in a patient with severe acute SARS-CoV-2 respiratory infection. European Heart Journal. 2020;41(32):3100–1. DOI: 10.1093/eurheartj/ehaa400
64. Dweck MR, Bularga A, Hahn RT, Bing R, Lee KK, Chapman AR et al. Global evaluation of echocardiography in patients with COVID-19. European Heart Journal Cardiovascular Imaging. 2020;21(9):949–58. DOI: 10.1093/ehjci/jeaa178
65. Skulstad H, Cosyns B, Popescu BA, Galderisi M, Salvo GD, Donal E et al. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel. European Heart Journal – Cardiovascular Imaging. 2020;21(6):592–8. DOI: 10.1093/ehjci/jeaa072
66. Linschoten M, Asselbergs FW. CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. European Heart Journal. 2020;41(19):1795–6. DOI: 10.1093/eurheartj/ehaa280
67. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;5(11):1265–73. DOI: 10.1001/jamacardio.2020.3557